Skip to main content
. Author manuscript; available in PMC: 2014 Apr 1.
Published in final edited form as: Biomaterials. 2013 Feb 4;34(12):3110–3119. doi: 10.1016/j.biomaterials.2013.01.037

Figure 5.

Figure 5

Western blotting data indicate that p5RHH (A) is approximately 5-fold less efficient than Lipofectamine 2000 (B) at initiating a decrease in STAT3 protein levels in B16 cells. RT-PCR data show that p5RHH (C) loses activity at concentrations below 50nM while Lipofectamine 2000 (D) exhibits activity at doses as low as 10nM. B16 viability analysis via Alamar Blue demonstrates that p5RHH (E) transfection leads to a decrease in B16 viability by silencing oncogene expression in a sequence specific manner whereas Lipofectamine2000 (F) causes nonspecific dose dependent cytotoxicity.